Radiobiological modelling applied to Unsealed Source (radio) Therapy

Similar documents
New Thinking on Fractionation in Radiotherapy

Dosimetry and radiobiology for Peptide Receptor Radionuclide Therapy

COMPARISON OF RADIOBIOLOGICAL EFFECTS OF CARBON IONS TO PROTONS ON A RESISTANT HUMAN MELANOMA CELL LINE

Radiobiology & Radiobiological Modelling in Radiotherapy, March 2015, Port Sunlight UK. PROGRAMME (final)

Radiobiological principles of brachytherapy

Radiation Damage Comparison between Intensity Modulated Radiotherapy (IMRT) and Field-in-field (FIF) Technique In Breast Cancer Treatments

Ranking radiotherapy treatment plans: physical or biological objectives?

Medical Physics 4 I3 Radiation in Medicine

RADIOBIOLOIGCALLY BASED TREATMENT PLANNING: THE NEXT FRONTIER. Teddy LaMaster, MS

Physical Bases : Which Isotopes?

The Promise and Pitfalls of Mechanistic Modeling in Radiation Oncology

RADIOBIOLOGICAL PRINCIPLES IN INTRAVASCULAR IRRADIATION

Cell survival following high dose rate flattening filter free (FFF) and conventional dose rate irradiation

An introduction to medical imaging and radiotherapy: Current status and future directions I

Isoeffective Dose Specification of Normal Liver in Yttrium-90 Microsphere Radioembolization*

Radiobiological Models in Brachytherapy Planning and Evaluation

Clinical Applications of Brachytherapy Radiobiology. Radiobiology is Essential

Therapeutic ratio - An Overview. Past Present Future Prof Ramesh S Bilimaga

CHAPTER TWO MECHANISMS OF RADIATION EFFECTS

Figure 1.1 PHITS geometry for PTB irradiations with: broad beam, upper panel; mono energetic beams, lower panel. Pictures of the setups and of the

Hampton University Proton Therapy Institute

What is radiation quality?

The Four R s. Repair Reoxygenation Repopulation Redistribution. The Radiobiology of Small Fraction Numbers. The Radiobiology of Small Fraction Numbers

The temporal pattern of dose delivery in external beam radiotherapy

Individualised Treatment Planning for Radionuclide therapy (Molecular Radiotherapy)

Use of radiation to kill diseased cells. Cancer is the disease that is almost always treated when using radiation.

Determination and Use of Radiobiological Response Parameters in Radiation Therapy Optimization. Panayiotis Mavroidis

BASIC CLINICAL RADIOBIOLOGY

Radiation Oncology. Initial Certification Qualifying (Computer-based) Examination: Study Guide for Radiation and Cancer Biology

IART and EBRT, an innovative approach

Joint ICTP-IAEA Advanced School on Internal Dosimetry. Trieste, April 2010

The Impact of Cobalt-60 Source Age on Biologically Effective Dose in Gamma Knife Thalamotomy

Radiobiology of fractionated treatments: the classical approach and the 4 Rs. Vischioni Barbara MD, PhD Centro Nazionale Adroterapia Oncologica

ADVANCES IN RADIATION TECHNOLOGIES IN THE TREATMENT OF CANCER

Fractionation: why did we ever fractionate? The Multiple Fractions School won! Survival curves: normal vs cancer cells

PHY138Y Nuclear and Radiation

Imaging of Scattered Radiation for Real Time Tracking of Tumor Motion During Lung SBRT

Quantitative Theranostics in Nuclear Medicine

ABSTRACTS FOR RADIOTHERAPY STANDARDS USERS MEETING. 5 th June 2007

Chapter 14 Basic Radiobiology

Peak temperature ratio of TLD glow curves to investigate the spatial variation of LET in a clinical proton beam

Rob Glynne-Jones Mount Vernon Cancer Centre

Biological/Clinical Outcome Models in RT Planning

Assessing the shift of radiobiological metrics in lung radiotherapy plans using 2D gamma index

Overview of Clinical and Research Activities at Georgetown University Hospital

4.1.1 Dose distributions LKB effective volume or mean liver dose? The critical volume model TUMOUR CONTROL...

Neutrons. ρ σ. where. Neutrons act like photons in the sense that they are attenuated as. Unlike photons, neutrons interact via the strong interaction

METROLOGY TO SUPPORT INNOVATION IN MOLECULAR RADIOTHERAPY. Glenn Flux

Assistant Professor Department of Therapeutic Radiology Yale University School of Medicine

Therapeutic Medical Physics. Stephen J. Amadon Jr., Ph.D., DABR

In-silico study to compare proton versus photon radiotherapy: a modelization based decision protocol ProtonShare Project

ALPHA PARTICLE MICRODOSIMETRY IN THE LUNG

Clinical considerations of RBE in proton therapy

Application of the concept of biologically effective dose (BED) to patients with Vestibular Schwannomas treated by radiosurgery

APPLICATIONS OF RADIATION IN MEDICINE. Kirstin Murray BSc (Hons) Radiotherapy & Oncology

Transition to Heterogeneity Corrections. Why have accurate dose algorithms?

UNC-Duke Biology Course for Residents Fall

Protons Monte Carlo water-equivalence study of two PRESAGE formulations for proton beam dosimetry J. Phys.: Conf. Ser.

Clinical application of intensity and energy modulated r adiother apy with photon and electron beams. Xiangkui Mu

Dose escalation in permanent brachytherapy for prostate cancer: dosimetric and biological considerations*

Neutron Radiotherapy: Past, Present, and Future Directions

POSTGRADUATE INSTITUTE OF MEDICINE UNIVERSITY OF COLOMBO MP (CLINICAL ONCOLOGY) PART I EXAMINATION - AUGUST Time : p.m p.m.

Radiobiologia: High dose per fraction. Lidia Strigari Laboratorio di Fisica Medica e Sistemi Esperti SBRT

Design of a BSA for Producing Epithermal Neutron for BNCT

PRINCIPLES and PRACTICE of RADIATION ONCOLOGY. Matthew B. Podgorsak, PhD, FAAPM Department of Radiation Oncology

Use of Bubble Detectors to Characterize Neutron Dose Distribution in a Radiotherapy Treatment Room used for IMRT treatments

Dosimetry comparison of orthovoltage x-ray and 137 Cs irradiation of the murine bone marrow compartment Matthew Belley

Advances in external beam radiotherapy

Proton and heavy ion radiotherapy: Effect of LET

I. Equipments for external beam radiotherapy

Can we deliver the dose distribution we plan in HDR-Brachytherapy of Prostate Cancer?

Quantitative Imaging: A hospital physicist s perspective James Scuffham

Dosimetric Uncertainties and Normal Tissue Tolerance. Ellen D Yorke Memorial Sloan Kettering Cancer Center New York City

The Radiobiological Four "R"s of Hypofractionation. Brian Marples PhD Beaumont Health Systems

Research Article (Radio)Biological Optimization of External-Beam Radiotherapy

Heterogeneity Corrections in Clinical Trials

Radiation Dose Response LQ model, RBE, LET, OER, TCP & NTCP

Biological Indices for IMRT Evaluation and Optimization

TFY4315 STRÅLINGSBIOFYSIKK

Hypofractionation and positioning in breast cancer radiation. John Hardie, M.D., Ph.D. November 2016

Modelling the induction of cell death and chromosome damage by therapeutic protons

The Radiation Biology of Dose Fractionation: Determinants of Effect

Theragnostics for bone metastases. Glenn Flux Royal Marsden Hospital & Institute of Cancer Research Sutton UK

Clinical Implementation of patient-specific dosimetry, comparison with absorbed fraction-based method

Evaluation of Normal Tissue Complication Probability and Risk of Second Primary Cancer in Prostate Radiotherapy

Overview of Advanced Techniques in Radiation Therapy

8/2/2018. Disclosures. In ICRU91: SRT = {SBRT/SABR, SRS}

Standardization of dosimetry practices for small and large animal irradiation in radiobiological studies

Biologically Based Treatment Planning X. Allen Li

Cardiovascular disease after radiation therapy

HDR Applicators and Dosimetry*

Implementation of advanced RT Techniques

The Critical Importance of High Quality in Radiation Therapy

The dependence of optimal fractionation schemes on the spatial dose distribution

Radiation Biology & Radiation Therapy

HEALTH RISKS FROM EXPOSURE TO FAST NEUTRONS. Prof. Marco Durante

Image Guided Proton Therapy and Treatment Adaptation

Measurement of Dose to Implanted Cardiac Devices in Radiotherapy Patients

Optimising Radiotherapy Using NTCP Models: 17 Years in Ann Arbor

The bootstrap method to improve statistical analysis of dosimetric data for radiotherapy outcomes

Transcription:

Radiobiological modelling applied to Unsealed Source (radio) Therapy Alan E. Nahum Physics Department Clatterbridge Cancer Centre NHS Foundation Trust Bebington, Wirral CH63 4JY UK alan.nahum@clatterbridgecc.nhs.uk Nuclear Medicine Metrology (NM 3 ), National Physical Laboratory, 21 November 2014

Acknowledgements Per Nilsson Katarina Sjögreen Gleisner Mark Konijnenberg Glenn Flux Ralph McCready Emiliano Spezi & Nick Patterson (Velindre) Julian Uzan, Colin Baker, Anthony Carver (Clatterbridge) Don Chapman (British Columbia)

Contents Radiobiology refresher: LQ model; doserate Brief overview of TCP & NTCP models in external-beam therapy Special radiobiological features of MRT Is the Radiobiological Quality of MRT sources the same as that of megavoltage EBRT beams? TCP applied to MRT I-131/thyroid: case study Summary & Future perspectives

Radiobiology a brief refresher The Linear-Quadratic model of cell-killing - two very different mechanisms : Single-hit killing: non repairable - ad Sublethal lesions: singly repairable but can combine to yield bd 2 killing a-killing is unrepairable so makes no difference how it is delivered spaitally or temporally - cannot be influenced by dose rate, fractionation, intensity modulation etc. b-killing is TWO hit, therefore time-dependent : prolonged overall irradiation time will reduce killing due to repair of first lesion before second one arrives 4

The effect of delivery time i.e. dose rate Dose-rate effect for a human melanoma cell-line (Steel,1986) Dose repair effects between 1 Gy/min and 0.1 Gy/min (e.g. slow IMRT) may be significant. Also for SBRT with 3 x 15-20 Gy: overall time is 20-30 min. Low dose rate means b = 0 ; all cell killing is by the a mechanism 5

Are all (therapy) radiations equally effective, per unit dose? Radiobiological effect of different radiations is often expressed in terms of RBE: RBE = Relative Biological Effectiveness = Ratio of doses D ref /D X to produce a given biological effect ref is generally taken as 60 Co gamma rays.

40 kv x-rays was the quality under investigation

The RBE of other Radiation Qualities Reference radiation: Cobalt 60 g - 1.25 MeV Ultra-soft x-rays - around 3.4 for C X-rays (V79 hamster cells) where secondary electrons all below 1 kev! e.g. Goodhead and Nikjoo, Int. J. Rad. Biol. 55 513-529 (1989) Megavoltage x-rays, electrons indistinguishable from Cobalt-60, less effective than 250 kv x-rays e.g. Amols, Laguex and Cagna Radiation Research 105 58-67 (1986)

kv Electron Fluence Per unit Dose Megavoltage 1 kev

What about the radionuclides used in MRT?

Monte-Carlo (GEANT4) work by Nick Patterson and Emiliano Spezi (Velindre cancer centre,cardiff) X-rays Kilovolt. Megavolt. Ra-223 a-emitter?? Lu-177 and I-131 are predicted to be more radiobiologically effective than P-31 and Y-90 which are equivalent to megavoltage photons 1 kev

These graphs explain why all megavoltage qualities have essentially identical radiobiological effectiveness this simplifies treatment planning: doses can simply be added, irrespective of beam direction and depth The marked increase in electron fluence per unit dose at low energies for all kilovoltage qualities over that for megavoltage is consistent with the increased RBE of kilovoltage x-rays The b-emitters we have looked at (I-131, Y-90 etc.) have a value of (1 kev)/d very close to that of megavoltage x-rays (EBRT). e- E

TCP and NTCP models in external-beam therapy

Modelling the probability of tumour control (TCP) TCP e -N s Where N s is the average number of surviving cells following irrradiation

SURVIVING FRACTION N s from the Linear Quadratic (LQ) model 2-Gy 0.6 0.3 2 fractions CELL KILL IN 2-GY FRACTIONS 1 0.876341 1 0.749762 0.1 0 2 4 6 8 10 12 0.626254 0.01 0.510686 0.001 0.40657 0.316004 0.0001 0.239788 1E-05 0.177639 1E-06 0.128478 1E-07 0.090718 1E-08 0.0795 1E-09 0.068017 1E-10 0.056812 1E-11 0.046328 1E-12 0.036883 1E-13 0.028667 0.021753 1E-14 0.016115 1E-15 0.011655 1E-16 0.00823 DOSE(Gy) 0.007212 0.00617 Clonogenic cells remaining after n fractions: - d d 2 d d 2 d d 2 N N e a b - e a b - e a b Single dose 2-Gy f ractions s 0 N after 1 st fraction N after 2 nd fraction... n times With the exception of fraction sizes above 10 Gy where the LQ model may no longer be valid and at doses less than 0.6 Gy (low dose hypersensitivity)

After n fractions of dose, d (Gy): b Ns ( VCTV c) exp -and 1 d ln(2) a T -T T d k Initial clonogen number Total Dose D LQ model Tumour repopulation c a,b T k T d clonogen density (estimated or fitted) radiosensitivities of the tumour clonogens (fitted via LQ model), delay before repopulation (days) clonogen doubling time (days)

Fit TCP parameters to clinical data population individual

Extension to inhomogeneous dose distributions DVHs summarise the dose distributions in a convenient way Volume Differential DVH Assume cells in each single dose bin j receive uniform total dose D j v j N 0, j c v j Total no. surviving cells, D j Dose N ( a ) N N e i i, j 0, j j j Clonogen density bi -ai Dj 1 d j ln( 2) ai T-T T d k

Effect of dose non-uniformity on TCP Tumour dose distribution (differential DVH) normally distributed with varying width but constant mean dose = 60 Gy. Inter-patient radiosensitivity s a varied from 0 to 0.05 to 0.10 to 0.15 s a 19

Iodine-131 therapy for thyroid cancer (half-life 8.02 days) The facts very high administered activity (AA) required for long-term remission ca. 100 mci or 3.7 GBq Assuming 10% uptake in the thyroid gland, and a mass of 10 g, this AA corresponds to an (equilibrium) absorbed dose of 1000 Gy Should we need such sky-high doses to achieve a high (say 99%) tumour control? Let s see what the TCP model says...

TCP TCP analysis ( Marsden model) using BioSuite Parameters a = 0.2 Gy -1 s a = 0.05 Gy -1 b = 0 (a/b v. high) N o = 10 7 clonogens 50 100 150 Dose (Gy) Result: 99% TCP obtained with 142 Gy

99% TCP obtained with 142 Gy (for the most conservative assumptions on radiosensitivity, clonogen number etc.) But 1000 Gy found to be necessary in clinical practice! Why?

BioSuite: TCP (and NTCP) optimization software Freeware, Calculates (from DVHs e.g. from Eclipse or Pinnacle format): TCP (Marsden model) - the user has full control over the parameters NTCP (LKB, RS models) as a function of (total) dose and number of fractions; Iso-NTCP customised prescription doses; TCP at iso-ntcp for variable number of fractions Available from: alan.nahum@clatterbridgecc.nhs.uk

Take home messages I The low doserates in MRT mean that b 0 in the LQ expression for cell-killing The cell-killing per unit dose of most MRT sources will be very similar to that of megavoltage x-rays. Electron fluence (at 1 kev) per unit dose is a promising surrogate metric for the dependence of a (and b) on radiation quality Radiobiological models for TCP (mechanistic) and NTCP (quasi-mechanistic) for external-beam RT are well established (published around 1990-92)

Take home messages II TCP modelling applied to e.g. I-131 for ca. Thyroid (assuming quasi-uniform uptake) predicts 100% cure rate for much lower activities than those clinically required probable explanation is HETEREGENEOUS uptake (cf. Sgouros et al 2008) Full Dose-Volume Histograms (of reasonable accuracy) will be required for reliable predictions of tumour control probability BioSuite freeware (Uzan and Nahum Br. J. Radiol. 2012) available on request

Thank you for your attention